Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPR vs High-dose Melphalan in Newly Diagnosed Multiple Myeloma
NCT00551928Phase 3Completed
- Sponsor
- Fondazione EMN Italy
- Start
- Jun 2007
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenalidomide in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Started Jun 2007; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00551928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551928.